北京航天长峰股份有限公司 营业收入扣除情况表 专项核查报告 致同会计师事务所（特殊普通合伙） 目 家 专项核查报告 公司 2024年度营业收入扣除情况表及说明 1-3 I F コココ コココココ a a m a s a p ■ 北京航天长峰股份有限公司 营业收入扣除情况表专项核查报告 致同专字(2025)第 110A010621 号 北京航天长峰股份有限公司全体股东: 门 日 日 ■ ■ ■ ■ ■ 日 日 日 日 日 日 日 日 日 Thornton 我们接受委托,在审计了北京航天长峰股份有限公司(以下简称"航天 长峰公司"）2024年 12月 31日的合并及公司资产负债表,2024年度的合并及 公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及财务 报表附注的基础上,对后附的《航天长峰公司 2024年度营业收入扣除情况表 及说明》(以下简称"营业收入扣除情况表")进行了专项核查。 按照《上海证券交易所股票上市规则》(以下简称"上市规则")和 《上海证券交易所上市公司自律监管指南第 2号 -- 业务办理》"第七号 财 务类退市指标:营业收入扣除"(以下简称"自律监管指南")的有关规定, 编制营业 ...

本报告依据中国资产评估准则编制 北京航天长峰股份有限公司拟进行商誉减值测 试涉及的航天柏克(广东)科技有限公司包含商 誉的资产组可收回金额 资产评估报告 中企华评报字(2025)第 6310 号 (共一册,第一册) 北京中企华 任公司 北京中介 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020110202500574 | | | --- | --- | --- | | 合同编号: | PG20250020601000 | | | 报告类型: | 法定评估业务资产评估报告 | | | 报告文号: | 中企华评报字(2025)第6310号 | | | 报告名称: | 北京航天长峰股份有限公司拟进行商誉减值测试涉及的航天柏克 (广东)科技有限公司包含商誉的资产组可收回金额资产评估报告 | | | 评估结论: | 239.905.700.00元 | | | 评估报告日: | 2025年04月25日 | | | 评估机构名称: | 北京中企华资产评估有限责任公司 | | | 答名人员: | 李学奇 (资产评估师) | 正式会员 编号: 11230150 | | | 云丹丹 (资产评估师) ...

北京航天长峰股份有限公司 作为公司的独立董事，我本人及直系亲属、主要社会关系不在该 公司或其附属企业任职、没有直接或间接持有公司已发行股份的1% 或1%以上、不是公司前十名股东、不在直接或间接持有公司已发行股 份5%或5%以上的股东单位任职、不在公司前五名股东单位任职、不在 公司控股股东、实际控制人的附属企业任职；本人与公司及其控股股 东、实际控制人或者其各自的附属企业无业务往来、没有为公司或其 附属企业提供财务、法律、咨询、保荐等服务、没有从上市公司及其 主要股东或有利害关系的机构和人员取得额外的、未予披露的其他利 益。 因此不存在影响独立性的情况。 二、年度履职情况 （一）参加董事会、股东大会会议情况。 报告期内，公司共组织召开董事会会议 7 次，股东大会 5 次，会 议的召集、召开均符合法定程序。本人按时出席了董事会及股东大会 会议，认真审阅会议相关材料，积极参与各议案的讨论，与公司管理 层进行充分沟通，了解公司的经营目标与规划，对会议审议议案均投 了赞成票。报告期内，本人出席董事会和股东大会的具体情况如下： 2024 年度独立董事述职报告 作为北京航天长峰股份有限公司（以下简称"公司"或"航天长 峰" ...

北京航天长峰股份有限公司 2024 年度独立董事述职报告 作为北京航天长峰股份有限公司（以下简称"公司"或"航天长 峰"）的独立董事，我严格按照《中华人民共和国公司法》《上市公 司治理规则》《上市公司独立董事管理办法》《上海证券交易所股票 上市规则》等法律法规及《公司章程》《公司独立董事管理办法》等 相关规定和要求，恪尽职守，勤勉尽责，及时了解公司的业务发展状 况、财务运作状况，全面关注公司的成长，积极出席相关会议，认真 审议董事会各项议案，认真履行了独立董事的职责。有效保证了董事 会决策的科学性和公司运作的规范性，切实维护了全体股东尤其是中 小股东的合法权益。现将本人2024年度履行职责情况报告如下： 王本哲，1959年9月出生，公共管理硕士，中央财经大学会计学 专业副教授。曾担任河南豫光金铅股份有限公司独立董事；北京康斯 特仪表科技股份有限公司独立董事、重庆三峡水利电力（集团）股份 有限公司独立董事。主要研究集中在会计理论与实务领域、会计制度 设计等。 作为公司的独立董事，我本人及直系亲属、主要社会关系不在该 公司或其附属企业任职、没有直接或间接持有公司已发行股份的1% 或1%以上、不是公司前十名股东、不 ...

北京航天长峰股份有限公司 因此不存在影响独立性的情况。 二、年度履职情况 （一）参加董事会、股东大会会议情况。 2024 年度独立董事述职报告 作为北京航天长峰股份有限公司（以下简称"公司"或"航天长 峰"）的独立董事，我严格按照《中华人民共和国公司法》《上市公 司治理规则》《上市公司独立董事管理办法》《上海证券交易所股票 上市规则》等法律法规及《公司章程》《公司独立董事管理办法》等 相关规定和要求，恪尽职守，勤勉尽责，及时了解公司的业务发展状 况、财务运作状况，全面关注公司的成长，积极出席相关会议，认真 审议董事会各项议案，认真履行了独立董事的职责，有效保证了董事 会决策的科学性和公司运作的规范性，切实维护了全体股东尤其是中 小股东的合法权益。现将本人2024年度履行职责情况报告如下： 一、独立董事的基本情况 惠汝太，1951年生，1975年毕业于山东医学院医疗系，1977年— 1978年在北京大学人民医院内科进修，1979年—1982年考入中国协和 医科大学高血压专业攻读硕士学位，毕业留院担任心内科主治医师， 1987年—1992年在加拿大蒙特利尔临床医学研究所攻读临床科学博 士学位，1993年—1996 ...

Financial Performance - The company's net profit attributable to shareholders for 2024 was -245.94 million RMB, a decline from -235.21 million RMB in 2023[5]. - Total operating revenue for 2024 was 1.16 billion RMB, representing a decrease of 16.09% compared to 1.38 billion RMB in 2023[22]. - The net cash flow from operating activities was -12.23 million RMB, worsening from -3.47 million RMB in the previous year[22]. - The total assets at the end of 2024 were 3.72 billion RMB, down 6.56% from 3.98 billion RMB at the end of 2023[23]. - The net assets attributable to shareholders decreased by 13.23% to 1.61 billion RMB from 1.85 billion RMB in 2023[23]. - The company reported a revenue of 1.16 billion RMB in 2024, with a net profit attributable to shareholders of -246 million RMB, indicating a significant decline in performance compared to previous years[24]. - The company recorded a basic earnings per share of -0.5259 RMB in 2024, compared to -0.5030 RMB in 2023[24]. - The weighted average return on equity improved slightly to -14.20% in 2024 from -14.33% in 2023[24]. - Net profit for the period was -265 million RMB, with a net profit attributable to shareholders of -246 million RMB[47]. Revenue Breakdown - Revenue from the high-end medical equipment sector decreased by 79.99% year-on-year, while net profit fell by 65.5 million RMB[25]. - The military electronics sector experienced an 11.43% decline in revenue year-on-year, with net profit improving by 33.86 million RMB, primarily due to a 30.27% drop in infrared optoelectronic business revenue[25]. - The public safety sector's revenue decreased by 7.53% year-on-year, with net profit declining by 37.63 million RMB, attributed to insufficient market demand and increased impairment provisions[25]. - The company achieved operating revenue of 1.16 billion RMB, a year-on-year decrease of 16.09% due to reduced income from public safety and military electronic infrared optical businesses[47]. Strategic Initiatives - The company plans not to distribute profits or increase capital reserves for 2024 due to overall performance losses[5]. - The company plans to address the decline in high-end medical equipment sales through market expansion strategies[25]. - The company is focusing on core development strategies and has completed mid-term evaluations and adjustments of the "14th Five-Year Plan"[37]. - The company is actively promoting new products and technologies, including the NO inhalation therapy device, and has published two provincial standards[44]. - The company is committed to the development of high-end medical equipment, focusing on domestic production and innovation[41]. - The company is enhancing its market position and influence in the aerospace defense industry through strategic resource allocation[37]. - The company is focusing on optimizing traditional power products and developing overall solutions for different application scenarios in the power sector[86]. Research and Development - The company’s total R&D investment amounted to 9,204.70 million RMB, representing 7.94% of total operating revenue[62]. - The company has 245 R&D personnel, making up 17.66% of the total workforce[63]. - The company launched 79 self-funded R&D projects, with 38 new projects initiated during the year[64]. - The company is focusing on high-tech, high-value-added product development, including advanced medical equipment and military electronics[65]. - The company is investing in R&D to address technological innovation risks, focusing on key core technologies and establishing partnerships with research institutions[96]. Governance and Compliance - The company has established a governance mechanism that enhances decision-making efficiency and reduces risks through clear authority and responsibility[100]. - The company emphasizes transparency and timely information disclosure to manage investor relations effectively[100]. - The company has implemented measures to ensure the independence of its operations and governance structure, complying with relevant laws and regulations[101]. - The company’s board of directors and supervisory board are functioning effectively, ensuring compliance with governance rules[102]. - The company has a clear plan for future governance improvements, focusing on risk management and operational efficiency[100]. Environmental and Social Responsibility - The company invested 5.136 million yuan in environmental protection during the reporting period[137]. - The company has identified 21 pollution discharge points and implemented management measures to enhance responsibility[139]. - All units have passed ISO 14001:2015 environmental management system certification in 2024[144]. - The company has organized training for over 200 employees on energy conservation and environmental protection laws and regulations[145]. - The company engaged in consumption assistance, purchasing local specialty foods worth 244,900 yuan to support targeted poverty alleviation[148]. Shareholder and Market Activities - The company repurchased and canceled a total of 72,150 shares, with an average price of 51.21[104]. - The total number of shares repurchased and canceled amounts to 69,1020, with a total value of 444.16 million[104]. - The company reported a total revenue of 51,444.36 million yuan and a net loss of 8,538.35 million yuan for the period[81]. - The company aims to achieve a revenue growth target of 15% year-over-year in the next fiscal year[105]. - The largest shareholder, China Aerospace Science and Industry Corporation, holds 141,150,722 shares, representing 30.13% of total shares[197].

Financial Performance - The company reported a revenue of CNY 99,810,834.68 for Q1 2025, a decrease of 33.89% compared to CNY 150,972,476.99 in the same period last year[4] - Total operating revenue for Q1 2025 was RMB 99,810,834.68, a decrease of 34% compared to RMB 150,972,476.99 in Q1 2024[19] - The net profit for Q1 2025 was a loss of CNY 48,213,192.40, compared to a loss of CNY 47,430,829.62 in Q1 2024, indicating a slight increase in losses of about 1.64%[21] - The total comprehensive income for Q1 2025 was a loss of CNY 48,213,192.40, compared to a loss of CNY 47,430,829.62 in Q1 2024, showing a slight increase in losses of about 1.64%[21] - The company's revenue for Q1 2025 was CNY 3,837,207.44, a decrease of 60.7% compared to CNY 9,751,509.56 in Q1 2024[30] - Operating profit for Q1 2025 was CNY -17,142,835.92, an improvement from CNY -26,261,635.18 in Q1 2024[30] - Net profit for Q1 2025 was CNY -17,139,835.82, compared to CNY -26,262,180.56 in Q1 2024, indicating a reduced loss[30] Cash Flow and Liquidity - The net cash flow from operating activities was CNY -130,862,574.77, worsening from CNY -72,483,482.20 in the previous year[5] - The cash flow from operating activities for Q1 2025 was a net outflow of CNY 130,862,574.77, worsening from a net outflow of CNY 72,483,482.20 in Q1 2024[23] - The total cash and cash equivalents at the end of Q1 2025 were CNY 653,264,910.70, down from CNY 848,867,259.38 at the end of Q1 2024, reflecting a decrease of approximately 23%[24] - The cash flow statement indicates a challenging liquidity position with a significant decrease in cash reserves compared to the previous period[34] - The company's cash flow from operating activities showed a significant decrease in cash outflows, with total cash outflows of CNY 20,942,844.61 in Q1 2025 compared to CNY 40,434,963.40 in Q1 2024[33] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,593,449,934.15, a decrease of 3.45% from CNY 3,721,891,711.89 at the end of the previous year[5] - Current assets totaled RMB 2,765,821,438.32 as of March 31, 2025, down from RMB 2,898,540,043.57 as of December 31, 2024, reflecting a decrease of approximately 4.6%[15] - Total liabilities amounted to RMB 1,906,121,151.47 as of March 31, 2025, compared to RMB 1,986,651,956.59 at the end of 2024, indicating a reduction of about 4%[17] - The company's total equity decreased to CNY 2,067,892,203.01 from CNY 2,085,032,038.83, a decline of 0.8%[28] - The total equity attributable to shareholders decreased to RMB 1,566,833,162.20 from RMB 1,609,351,070.15, reflecting a decline of approximately 2.6%[17] Operational Insights - The decline in revenue was primarily due to a significant drop in the infrared optoelectronic business and underperformance in high-end medical equipment deliveries[5] - The company aims to enhance profitability and operational control by focusing on aerospace defense and deep military-civilian integration industries[5] - The company signed more contracts in the military electronic power business compared to the previous year, indicating growth in this segment[5] - The company will continue to promote cost reduction and efficiency improvement initiatives[5] Research and Development - Research and development expenses for Q1 2025 were CNY 16,345,663.66, up from CNY 15,302,272.41 in Q1 2024, representing an increase of approximately 6.83%[20] - Research and development expenses for Q1 2025 were CNY 3,141,377.34, down from CNY 5,663,258.21 in Q1 2024, indicating a reduction of 44.4%[30] Shareholder Information - The top shareholder, China Aerospace Science and Industry Corporation, holds 30.1% of the shares[10] Government Support - The company received government subsidies amounting to CNY 3,407,911.50, which are closely related to its normal business operations[7] Financial Management - The company will not apply new accounting standards starting from 2025, maintaining current reporting practices[35] - The company's financial management team is led by key personnel including Xiao Haichao, Wang Xuan, and Sun Huajun, ensuring oversight of accounting practices[34]